Education
About Us
Working with TipRanks
Follow Us
Precision BioSciences (DTIL)
NASDAQ:DTIL
DTIL Stock Chart & Stats
$4.36
-$0.10(-2.09%)
At close: 4:00 PM EST
$4.36
-$0.10(-2.09%)
Day’s Range― - ―
52-Week Range$3.89 - $8.82
Previous CloseN/A
Volume55.33K
Average Volume (3M)199.69K
Market Cap
$101.34M
Enterprise Value$13.60M
Total Cash (Recent Filing)$44.87M
Total Debt (Recent Filing)$29.13M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Mar 17, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding24,071,750
10 Day Avg. Volume206,262
30 Day Avg. Volume199,693
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.46
Price to Sales (P/S)0.38
P/FCF Ratio-0.44
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue19.48
Enterprise Value/Gross Profit-20.23
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$45.00Price Target Upside932.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPBGENE-HBV produced measurable reductions in hepatitis B surface antigen in treated patients and provided clinical evidence of direct in vivo editing of HBV DNA, supporting the prospect of a durable antiviral effect.
Intellectual PropertyIssuance of a U.S. patent for optimized engineered meganucleases extends protection for the HBV-targeting ARCUS technology into 2042, enhancing commercial defensibility.
Safety ProfileRepeat dosing in the ELIMINATE-B program demonstrated a favorable hepatic safety profile with no dose-limiting toxicities or treatment-related serious adverse events and only transient liver enzyme elevations.
Bears Say
Patient Enrollment And AccessDiagnostic delays and financial barriers in rural or resource-limited populations risk constraining trial enrollment and future market access for advanced therapies, potentially slowing recruitment and commercialization.
Patient Retention And ComplianceFamilies facing misdiagnoses or forced trade-offs between clinic visits and essential income create retention and compliance risks that could increase trial dropouts and complicate outcome assessment.
Trial Design And Biomarker CriteriaLack of baseline HBsAg limits in eligibility criteria may introduce patient heterogeneity that complicates interpretation of efficacy signals and pose challenges for regulatory review or labeling.
Precision BioSciences News
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $3.89 and its highest was $8.82 in the past 12 months.
What is Precision BioSciences’s market cap?
Precision BioSciences’s market cap is $101.34M.
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is Mar 17, 2026 which is in 67 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Nov 03, 2025. The company reported -$1.84 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.5.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -0.54.
How many shares outstanding does Precision BioSciences have?
Precision BioSciences has 24,071,750 shares outstanding.
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of -$1.84 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went down -9.804%.
Which hedge fund is a major shareholder of Precision BioSciences?
Currently, no hedge funds are holding shares in DTIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precision BioSciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.00 (932.11% Upside)
$45.00 (932.11% Upside)
Blogger Sentiment
Bullish
DTIL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 426.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $33.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.0%
Last 30 Days ▲ 21.7%
Last 30 Days ▲ 21.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.97%
12-Months-Change
Fundamentals
Return on Equity
-205.16%
Trailing 12-Months
Asset Growth
-38.99%
Trailing 12-Months
Company Description
Precision BioSciences
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
DTIL Stock 12 Month Forecast
Average Price Target
$45.00
▲(932.11% Upside)
Technical Analysis
Ownership Overview
1.74% Insiders
2.93% Mutual Funds
12.46% Other Institutional Investors
81.00% Public Companies and
Individual Investors